Track PMV Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

PMV Pharmaceuticals, Inc. PMVP · Stock Open PMV Pharmaceuticals, Inc. in new tab

1.27 USD
EPS
-1.56
P/B
1.60
ROE
-99.42
Beta
1.51
Target Price
4.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 5, 2027
EPS-1.56
Book Value0.76
Price to Book1.60
Debt/Equity0.24
% Insiders2.364%
Estimates
Forward P/E-1.22
Forward EPS-0.99
Target Mean Price4.00

DCF valuation

Model fair value for PMV Pharmaceuticals, Inc. (PMVP)
Result
Sign in to run the valuation for PMVP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 4.00 USD (low 3.00, high 5.00) · as of 12 Nov 2026
Low 3.00
Mean 4.00
High 5.00
Price 1.27
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

PMV Pharmaceuticals, Inc. Logo PMV Pharmaceuticals, Inc. Analysis (PMVP)

United States Health Care Official Website Stock

Is PMV Pharmaceuticals, Inc. a good investment? PMV Pharmaceuticals, Inc. (PMVP) is currently trading at 1.27 USD. Market analysts have a consensus price target of 4.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: PMV Pharmaceuticals, Inc. is expected to release its next earnings report on March 5, 2027. The market consensus estimate for Forward EPS is -0.99.

Investor FAQ

Does PMV Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is PMV Pharmaceuticals, Inc.?

PMV Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 5, 2027. The company currently has a trailing EPS of -1.56.

Company Profile

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Exchange Ticker
NMS (United States) PMVP
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion